ArticleJournal of neuro-oncology2026

MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.

Nathalie Skarin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.